Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Me too...as a seller
Who would pay .25 per share of this POS?
Definite fat fingers. Someone didn’t proofread their order before hitting send and missed a couple of zeros.
And yet the pps changed not a bit. Weird.
The pps of MJNA has nothing to do with pending legality of cannabis. They need to get their financials in order, like debt and O/S, before anyone here gets rich.
And you’re buying that?
There no revenues is only the first of many issues with that list
Seems like this could be a bid deal for MJNA.....
SAN DIEGO, Oct. 10, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA), the first-ever publicly traded cannabis company in the United States, today announced that it has launched its newest brand, Dixie Botanicals Canada®, partnering with Canadian extraction and formulation company Salvation Botanicals, Ltd. ("Salvation").
Dixie Botanicals Canada® will be introducing its line of cannabidiol (CBD)-only, consumer-friendly products to the recently legalized Canadian cannabis market. All Dixie Botanicals Canada® products are crafted using expertly cultivated and scientifically-extracted cannabis oil and will be available in a variety of delivery methods including liquids, capsules, and oral sprays.
"The company is pleased to be launching this well-known and highly-regarded brand to such a promising market," said Medical Marijuana, Inc. Chief Executive Officer Dr. Stuart Titus. "Dixie Botanicals Canada now offers a collection of innovative, high-quality products while consistently meeting their ever-growing customers' needs."
The launch of Dixie Botanicals in Canada follows Medical Marijuana, Inc.'s recent announcement of its signed contract with Salvation. Through its new agreement with Salvation, Medical Marijuana, Inc. will continue to offer the same level of quality and expertise with many of these prestigious brands and products in Canada.
"Medical Marijuana, Inc. will continue to be a company of firsts by being one of the first companies to work with one of Canada's premium manufacturers to bring innovative products to market," said Medical Marijuana, Inc. Director of Canadian Operations, Kenneth Smith. "We are excited the see the many opportunities this new market brings and the many people who we're able to help get access to CBD through this new brand."
"Salvation is very pleased to be working with the Medical Marijuana, Inc. team," said Salvation Chief Finance Officer Rob McIntyre. "They bring a wealth of knowledge that will assist Salvation in providing the Canadian market with the highest quality products possible."
Medical Marijuana, Inc. produces industry-leading CBD brands including Dixie Botanicals®, Real Scientific Hemp Oil™ (RSHO™), Cannabis Beauty Defined®, HempMeds® and Phyto Animal Health™ in the United States and many other Latin American and European countries for distribution.
With what money will the shares be bought back?
Just got a Diamond email with a 40% off everything code:
columbus40
2019 should be an insane year for MJNA
conservative projection of over $150 million in revenue
If they made just a modest effort at reducing the debt this pps would fly.
Which means it’s time to local the boat
Good news or bad?
Slowly climbing back towards a Green Day here.
Anyone have an opinion on this?
LAS VEGAS, Oct. 08, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) ("CLS" or the "Company") today announced that it has entered into an agreement with a Canadian agent (the "Agent"), whereby the Agent will assist the Company in selling on a commercially reasonable efforts private placement basis, up to US$40 million aggregate principal amount of senior unsecured debentures (“Debentures”) with an issue price of US$1,000 per Debenture, convertible into units of the Company (the “Units”) at the option of the holder at a conversion price of US$0.80 per Unit (the “Conversion Price”) at any time prior to the close of business on the earlier of: (i) the last business day immediately preceding the maturity date of the Debentures, being the date that is three (3) years from the closing date of the Offering (the “Closing Date”), and (ii) the date fixed for redemption (as set out in the Debentures (the “Offering”).
Each Unit shall be comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant shall be exercisable into one Common Share at a price of US$1.10 per Warrant (the “Exercise Price”) for a period of 36 months from the Closing Date.
The Debentures will be unsecured obligations of the Company and will rank pari passu in right of payment of principal and interest and will be issued pursuant to the terms of a debenture indenture to be entered into between the Company and a debenture trustee to be determined. The Debentures shall bear interest at a rate of 8% per annum from the Closing Date, payable on the last business day of each calendar quarter. For a period of 18 months from the Closing Date, any interest payable shall automatically accrue and be capitalized to the principal amount of the Debenture and shall thereafter be deemed to be part of the principal amount of the Convertible Debenture.
Beginning on the date that is four (4) months plus one (1) day following the Closing Date, the Company may force the conversion of all of the principal amount of the then outstanding Debentures at the Conversion Price on not less than 30 days notice should the daily volume weighted average trading price of the common shares be greater than US$1.20 per common share for the preceding 10 consecutive trading days.
Upon a Change of Control (as defined in the Debentures) of the Company, holders of the Debentures will have the right to require the Company to repurchase their Debentures, in whole or in part on the date that is 30 days following notice of the Change of Control, at a price equal to 105% of the principal amount of the Debentures then outstanding plus accrued and unpaid interest thereon (the “Offer Price”). If 90% or more of the principal amount of the Debentures outstanding on the date of the notice of the Change of Control have been tendered for redemption, the Company will have the right to redeem all of the remaining Convertible Debentures at the Offer Price. The Debentures will also contain standard anti-dilution provisions.
Closing of the Offering is expected to occur in tranches on such dates as the Agent and the Company may agree and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals of the securities regulatory authorities.
Pursuant to the terms of the Offering, the Agent has been granted an option to increase the Offering by 15%, which option is exercisable by the Agents at any time up until the Closing Date.
The Company will pay a cash commission to the Agent equal to 6.0% of the aggregate gross proceeds of the Offering (the “Agent’s Fee”) payable in cash or Debentures. The Agent will receive a corporate finance fee equal to 2.5% of the gross proceeds of the Offering divided by the Conversion Price, payable in Units on the Closing Date. The Company will also issue warrants to the Agent exercisable for a period of 36 months from the Closing Date to acquire that number of Units which is equal to 6.0% of the aggregate gross proceeds of the Offering divided by the Conversion Price, at an exercise price that is equal to the Conversion Price.
The Company intends to use the net proceeds of the Offering to fund the upfront loan payment to In Good Health Inc., to fund construction activities at the Leicester facility, to complete improvements to the North Las Vegas cultivation facility and for general working capital purposes.
Yep. Diamond sent it to me in an email.
I stocked up on edibles using it.
Discount code: 50
Works
Market cap will lose to FOMO
Buy now....we’re headed higher.
They’ve been silent since switching accountants. They’re working on a name change, uplist, two or three associated companies and trying to get legit audited financials out.
It’s all good.
Looks like another BIG volume day. Shares are churning
What do you mean fills it’s available float?
How long have you been waiting?
Nice move!
Do I hear .425?
We seem stuck at .3599 for some reason.
Why would anyone sell at that pps?
This float is small enough, that if people HODL their shares instead of profit taking we’ll have another good day tomorrow.
Should we expect a pullback tomorrow or is this going to skyrocket like Tilray?
And the pps doesn’t move.
What’s it going to take to get the attention of new investors?
Oh right.....audited financials with over $100million in annual revenue, decreasing debt and decreasing O/S. Until we get that, the rest is just noise.
Agreed. INTV is dependent on BTC. When it rallies so do we. Pretty simple.
Maybe we get .25+ for eod?
Looks like you’re out of luck. I don’t think we’re seeing .80s ever again.
GRPS is one of the associated companies with RSHN
POTN also
This seems like potentially many millions in revenue to me. Anyone else?
SAN DIEGO, Oct. 2, 2018 /PRNewswire/ -- Medical Marijuana, Inc. MJNA, -0.06% the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brasil has released a new full-spectrum 5,000 mg cannabidiol (CBD) hemp oil liquid for the rapidly-expanding Brazil market.
"We are very excited to announce this new CBD hemp oil product in Brazil," said Medical Marijuana, Inc. Chief Executive Officer Dr. Stuart Titus. "The company is proud to be the first-ever to receive a permit to import CBD hemp oil products into Brazil and we will continue to stay relevant in the country by creating products that fit the needs of our Brazilian consumers."
This new 5000 mg product was developed to meet the new specifications of Brazilian doctors who plan to recommend the product to their patients. HempMeds® Brasil was the first company to receive an import permit for CBD in Brazil and, after a series of historic rulings, Brazilian Health Regulatory Agency ANVISA removed CBD from Brazil's prohibited substance use list, removed the substance's import tax and is now actively subsidizing the cost of CBD for those who need financial assistance.
"Our Company is thrilled that the Brazilian government has been willing to work with us to ensure our products can get into the hands of those who need them most," said HempMeds® Brasil Vice President Caroline Heinz. "It's incredible to see the public's response to our products and the rate at which the popularity of CBD hemp oil has spread here in Brazil."
There’s really not much that moves the needle here as far as PR’s go, is there?
Audited quarterly financials are desperately needed right about now.
That’s what’s Tilton authorized to buy back. It has nothing to do with what he’s actually going to buyback. That would take revenue.
Does that explain the sudden 20% spike?
3 weeks does not make you patient. Change your timeline and see what RSHN has done since July 1.
Patience is a requirement with this one. They’re going to easily pass $150 million in revenue for 2019. If they can decrease the debt and maybe reduce the O/S the pps should fly.
When, exactly, does pot stock season begin?
Everyday I see PRs about how huge the CBD/MJ market is going to be, but it’s not reflected in most of the stock pps.
Which means an upside breakout is imminent?